Advanced search×

[Emerging infectious diseases: the example of the Indian Ocean chikungunya outbreak (2005-2006)].

Bull Acad Natl Med 191(1):113-24; discussion 125-8 (2007) PMID 17645111

Factors known to trigger the emergence or re-emergence of infectious diseases include globalisation, population growth, migration, international trade, urbanisation, forest destruction, climate change, loss of biodiversity, poverty, famine and war. Epidemics not only lead to disastrous loss of human life but may also have catastrophic economic, political and social consequences. Outbreaks may rapidly jeopardize industry, trade or tourism in countries that are unprepared. Dengue is currently spreading throughout the tropics, while another arbovirus, chikungunya, infected 30 to 75% of the population in some parts of the Indian Ocean region between 2005 and 2006. Chikungunya is now spreading through India, where more than a million people have so far been infected. This viral disease can cause lasting disability, and the first deaths were recently reported in La Réunion and Mayotte. All countries are at risk from emerging or re-emerging diseases, but the consequences are far worse in poor countries. Microbial pathogens and wild mammals, birds and arthropods do not respect man-made borders. There is still time to act against this threat of emerging and re-emerging infectious diseases, through prevention, anticipation, monitoring and research.

Version: za2963e q8zae q8zbf q8zc9 q8zd0 q8zef q8zf2 q8zg6

Similar articles you may find interesting…

  1. Probabilistic Constructions of Computable Objects and a Computable Version of Lov\'asz Local Lemma

    arXiv:1305.1535 [cs.DM] 7 May 2013

    We show that an object with Required properties appears with some positive probability in some random Process. Can we use such arguments to prove the existence of a computable Infinite object? Sometimes yes: following [8], we show how the notion of a Layerwise computable mapping can be used to prove...
  2. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile acr...

    J Viral Hepat 20(6):395-403 (2013) PMID 23647956

    Study C209 evaluated the activity of telaprevir in treatment-naïve patients with genotypes 2 or 3 (G2, G3) hepatitis C virus (HCV) infection. Telaprevir monotherapy showed potent activity against HCV G2, but limited activity against G3. This analysis was performed to characterize HC...
  3. The emerging therapeutic role of antibody mixtures.

    Expert Opin Biol Ther (2013) PMID 23646883

    A body of evidence suggests that a mixture of therapeutic monoclonal antibodies (mAbs) may be better than a single antibody. Several strategies have been developed to achieve multiple targeting, including the administration of two or more mAbs to the patient, bispecific antibodies an...